Adverse Event Risk Up for >90 Days Versus >30 Days of Corticosteroids for Eczema
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 24, 2024 -- Use of oral corticosteroids for >90 days during one year is associated with a slightly increased risk of adverse events (AEs), according to a study published online July 19 in JAMA Network Open.
Yong Hyun Jang, M.D., Ph.D., from Kyungpook National University in Daegu, South Korea, and colleagues examined the association between long-term exposure to oral corticosteroids and occurrence of 11 AEs among adult patients with atopic dermatitis. Analysis included 164,809 cases and 328,303 controls.
The researchers found that 3.4 percent of cases and 3.2 percent of controls were exposed to oral corticosteroids for >30 days, while 0.4 percent in both groups were exposed to oral corticosteroids for >90 days. There was no increased risk of AEs with use of oral corticosteroids for >30 days (adjusted odds ratio, 1.00; 95 percent confidence interval, 0.97 to 1.04). However, the risk was higher with use of oral corticosteroids for >90 days (adjusted odds ratio, 1.11; 95 percent confidence interval, 1.01 to 1.23). For each cumulative or consecutive year of ever long-term use, there was a small elevation of risk for experiencing an AE.
"This study suggests that for patients with exacerbations of atopic dermatitis, limiting the duration of oral corticosteroid treatment to 90 days or less may limit adverse effects," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Early Dog Exposure May Modify Genetic Effect on Atopic Eczema Risk
MONDAY, June 9, 2025 -- Early-life dog exposure may modify the genetic effect of the single nucleotide variant rs10214237 on atopic eczema (AE) via IL7R, according to a study...
AI Three-Item Severity Score Can ID Eczema From Patient-Uploaded Images
FRIDAY, May 23, 2025 -- An artificial intelligence (AI) Three-Item Severity (TIS) score can identify eczema-affected areas and severity scores from user-uploaded images, according...
AAP Updates Guidelines for Pediatric Atopic Dermatitis Management
MONDAY, May 19, 2025 -- In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for the treatment of children...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.